MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR
{{output}}
MET-positive gastric cancer (GC) has a poor prognosis. In addition, targeting MET with monoclonal antibodies or tyrosine kinase inhibitors had limited success. We searched for additional genetic alterations that might explain the poor outcome of MET-positive G... ...
